John Renger, Chief Scientific Officer at Cerevel Therapeutics Holdings, Inc. (CERE), sold 110,000 shares at $40.19 ($4.5M) on 2022-08-10, disclosed to the SEC on 2022-08-12.
Open-market sale of $4.5M CERE by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.19 | 36,141 | $1.5M | 32.6% |
| 2 | $40.19 | 36,141 | $1.5M | 32.6% |
| 3 | $41.10 | 18,859 | $775K | 17.4% |
| 4 | $41.10 | 18,859 | $775K | 17.4% |
| Total | $40.50 avg | 110,000 | $4.5M | 100% |
| Filing → |
| CERE | SELL | 2022-10-06 | $750K | — | Filing → |
| CERE | SELL | 2022-08-09 | $1.0M | — | Filing → |
| CERE | SELL | 2022-07-22 | $750K | — | Filing → |